Apixaban in patients with atrial fibrillation
| Autor: | Connolly, Stuart J, Eikelboom, John, Joyner, Campbell, Diener, Hans-Christoph, Hart, Robert, Golitsyn, Sergey, Flaker, Greg, Avezum, Alvaro, Hohnloser, Stefan H, Diaz, Rafael, Talajic, Mario, Zhu, Wei Jun, Pais, Prem, Budaj, Andrzej, Parkhomenko, Alexander, Jansky, Petr, Commerford, Patrick, Tan, Ru San, Sim, Kui-Hian, Lewis, Basil S, Van Mieghem, Walter, Lip, Gregory Y H, Kim, Jae Hyung, Lanas-Zanetti, Fernando, Gonzalez-Hermosillo, Antonio, Dans, Antonio L, Munawar, Muhammad, O'Donnell, Martin, Lawrence, John, Lewis, Gayle, Afzal, Rizwan, Yusuf, Salim, Husted, Steen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Male
medicine.medical_specialty medicine.drug_class Pyridones Embolism Medizin Hemorrhage chemistry.chemical_compound Double-Blind Method Fibrinolytic Agents Edoxaban Risk Factors Internal medicine Atrial Fibrillation medicine Humans cardiovascular diseases Stroke Aged Proportional Hazards Models Aged 80 and over Aspirin business.industry Anticoagulant Hazard ratio Atrial fibrillation General Medicine Vitamin K antagonist Middle Aged medicine.disease chemistry Anesthesia Factor Xa Pyrazoles Apixaban Female business medicine.drug |
| Zdroj: | Connolly, S J, Eikelboom, J, Joyner, C, Diener, H-C, Hart, R, Golitsyn, S, Flaker, G, Avezum, A, Hohnloser, S H, Diaz, R, Talajic, M, Zhu, W J, Pais, P, Budaj, A, Parkhomenko, A, Jansky, P, Commerford, P, Tan, R S, Sim, K-H, Lewis, B S, Van Mieghem, W, Lip, G Y H, Kim, J H, Lanas-Zanetti, F, Gonzalez-Hermosillo, A, Dans, A L, Munawar, M, O'Donnell, M, Lawrence, J, Lewis, G, Afzal, R, Yusuf, S, AVERROES Steering Committee and Investigators & Husted, S 2011, ' Apixaban in patients with atrial fibrillation ', Briefings from the New England Journal of Medicine, vol. 364, no. 9, pp. 806-17 . https://doi.org/10.1056/NEJMoa1007432 |
| Popis: | A b s t r ac t Background Vitamin K antagonists have been shown to prevent stroke in patients with atrial fibrillation. However, many patients are not suitable candidates for or are unwilling to receive vitamin K antagonist therapy, and these patients have a high risk of stroke. Apixaban, a novel factor Xa inhibitor, may be an alternative treatment for such patients. Methods In a double-blind study, we randomly assigned 5599 patients with atrial fibrillation who were at increased risk for stroke and for whom vitamin K antagonist therapy was unsuitable to receive apixaban (at a dose of 5 mg twice daily) or aspirin (81 to 324 mg per day), to determine whether apixaban was superior. The mean follow up period was 1.1 years. The primary outcome was the occurrence of stroke or systemic embolism. Results Before enrollment, 40% of the patients had used a vitamin K antagonist. The data and safety monitoring board recommended early termination of the study because of a clear benefit in favor of apixaban. There were 51 primary outcome events (1.6% per year) among patients assigned to apixaban and 113 (3.7% per year) among those assigned to aspirin (hazard ratio with apixaban, 0.45; 95% confidence interval [CI], 0.32 to 0.62; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|